CN109745340A - A kind of method of drug therapy dry eyes after laser in situ keratomileusis - Google Patents
A kind of method of drug therapy dry eyes after laser in situ keratomileusis Download PDFInfo
- Publication number
- CN109745340A CN109745340A CN201711079199.1A CN201711079199A CN109745340A CN 109745340 A CN109745340 A CN 109745340A CN 201711079199 A CN201711079199 A CN 201711079199A CN 109745340 A CN109745340 A CN 109745340A
- Authority
- CN
- China
- Prior art keywords
- eye drops
- sodium hyaluronate
- laser
- eye
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The method of drug therapy dry eyes, LASIK postoperative patient, postoperative routine give 1g L after a kind of laser in situ keratomileusis‑1Fluorometholone eye drops+3g L‑1Ofloxacin eye drops add calf blood protein-removed extraction gel for eye use and sodium hyaluronate eye drops 4 times a day, add sodium hyaluronate (love is beautiful) eye drops 4 times a day, each treatment 1 month.
Description
Technical field
The present invention relates to a kind of methods of drug therapy dry eyes after laser in situ keratomileusis, specifically with one kind
The method of drug therapy dry eyes after laser in situ keratomileusis.
Background technique
Currently known Laser in Situ Keratomileusis (laser assisted in si-tu
Keratomileusis, LASIK) because postoperative complications are few, restore the advantages that fast, eyesight predictability is good have become current dioptric
The mainstream art formula of operation.But its damage for still having inevitably resulted in epithelial cell, nerve fibre, this is to lead to postoperative do
Eye, the main reason for associated with epithelial healing is bad.In addition, on the even excessive caused cornea of LASIK post-operative cornea matrix growth disorder
Visual quality decline caused by subcutaneous mist-like bleary (haze) is also one of problem in the urgent need to address at present.Restore angle as early as possible
The integrality of film epithelium, nerve fibre structure and function makes cornea rebirth stroma cell ordered arrangement, can extend tear film rupture
Time (break-up time, BUT) mitigates postoperative uncomfortable reaction, reduces infection chance, promote vision restoration.
Summary of the invention
General information；Choose myopia and myopic astigmatism patient 60 wherein, male 32, female 28, totally 120, according to art
Medication different random is divided into two groups afterwards, I group and II group each 60, postoperative follow-up on schedule.In research, the equal orthotropia of all objects,
Amblyopia and whole body system disease.All patients are without cornea surgery trauma history, no corneal degeneration, no whole body system disease and glue
Pathogenic disease, preoperative planning is without keratoconus and its risk factor, remaining stromal thickness > 280 μm.Refractive diopter was stablized in 2 years
More than, stop wearing contact lens > 1 week.
Test reagent；(trade name element Gao Jie, the emerging neat pharmacy in Shenyang are limited for 20% calf blood protein-removed extraction gel for eye use
Company), every 5g.1g L-1 sodium hyaluronate eye drops (trade name likes beautiful eye drops, Japanese Santen Pharmaceutical Co. Ltd.).
Method conventional line lasik surgery, postoperative routine give 1g L-1 fluorometholone eye drops+3g L-1 Ofloxacin drop
Ocular fluid, 3 times a day, totally 10 d, experimental group, which adds to be added with calf blood protein-removed extraction gel for eye use, control group, uses Sodium Hyaluronate
Eye drops in treatment is 4 times a day, to continue 3 months.Each center surgical procedure is complete using uniform machinery by the same doctor
At.
Observation item；9 indexs are observed and scored respectively at postoperative 1st month.Including visual fatigue, obscure
The subjective symptoms such as sense, foreign body sensation, sensation of dryness, tingling sensation and BUT, Schimer's test (Schirmer ' s Te I), cornea fluorescence
Dye (fluorescein staining, FS), tear fern tests sign.BUT, Schirmer ' Test I presses objective value
Record, remaining project are denoted as 0,1,2,3 point all in accordance with standards of grading, observe patient's compliance and adverse reaction.
Standards of grading；Subjective symptom: 0 point is asymptomatic；1 point is slight but does not influence to live；2 points are obvious for symptom, but
It can endure；3 points are clearly, to influence to live, can not endure.FS:0 points: negative;1 point: shallow-layer is dotted to be dispersed in spot, number
Mesh is 1~5;2 points: the dotted dyeing of apparent cornea, number is 6~1, including the abrasion that cornea table is shallow;3 points: very
The dotted dyeing of apparent cornea, number > 11 or shallow-layer corneal dyeing point merge slabbing.It is fern that tear fern, which tests 0 point,
Blade is complete；1 point is slight impaired；2 points are obvious imperfect；3 points are almost on-bladed.Statistical method application SPSS
18.0 statistical analysis softwares carry out statistical procedures, and using rank sum test, P < 0. 05 is that result has statistical significance.
As a result: gender in selected case, age, no difference of science of statistics (P > 0.05) between 2 groups of preoperative diopter.Each group medication
Effect: in addition to eye visual fatigue P>0.05, remaining each subjective symptom improves, and 2 groups of statistics have significant difference (P<0. 01).
Post-operative cornea dyeing and tear fern are tested 2 groups and are increased, but test group is less, and statistics has significant difference (P < 0. 01);
For Schirmer ' s Test I compared with increasing before medication, difference is statistically significant (P < 0. 05) after test group medication;Control group
Schirmer ' s Test I and 2 groups of medications front and back breakup time of tear film (BUT) no difference of science of statistics (P > 0.05).
Goal of the invention: Laser in Situ Keratomileusis (laser assistedinsi-tu
Keratomileusis, LASIK) because postoperative complications are few, restore the advantages that fast, eyesight predictability is good have become current dioptric
The mainstream art formula of operation.But its damage for still having inevitably resulted in epithelial cell, nerve fibre, this is to lead to postoperative do
Eye, the main reason for associated with epithelial healing is bad.In addition, on the even excessive caused cornea of LASIK post-operative cornea matrix growth disorder
Visual quality decline caused by subcutaneous mist-like bleary (haze) is also one of problem in the urgent need to address at present.Restore angle as early as possible
The integrality of film epithelium, nerve fibre structure and function makes cornea rebirth stroma cell ordered arrangement, can extend tear film rupture
Time (break-uptime, BUT) mitigates postoperative uncomfortable reaction, reduces infection chance, promote vision restoration.To 2016 2
~April uses calf blood protein-removed extraction gel and sodium hyaluronate ocular fluid medicine in the patient that our hospital implements lasik surgery respectively
Object, it is glimmering to breakup time of tear film (break up time, BUT), Schimer's test (Schirmer ' sTest I), cornea later
Light dyeing, tear fern test situation carry out analysis and obtain following result.
Technical solution: extracting LASIK postoperative patient in certain period of time, is randomly divided into test group and control group, and each 30
(60).Postoperative routine gives 1g L-1 fluorometholone eye drops+3 g L-1 ofloxacin eye drops, and 4 times a day, test group adds
Calf blood protein-removed extraction gel for eye use and sodium hyaluronate eye drops, control group add sodium hyaluronate (love is beautiful) eye drops daily 4
It is secondary, each treatment 1 month.Month after operation compares patient's subjective symptom, objective sign and evaluates whole curative effect.Subjectivity refers to
Mark includes visual fatigue, fuzzy sense, foreign body sensation, sensation of dryness, tingling sensation.Objective indicator includes breakup time of tear film, lacrimal secretion examination
Test (Schirmer ' sTestI), cornea fluorescent staining, the test of tear fern.All data are all made of the progress of SPSS18.0 software
Processing.
It is postoperative to can be relieved LASIK the utility model has the advantages that calf blood protein-removed extraction gel for eye use safety, compliance are good for invention
Ocular malaise symptoms, and have certain effect to corneal epithelium after LASIK and neural restoration, lacrimal secretion, tear film stability protection,
And have no that cornea rebirth blood vessel generates or exacerbation, haze and other poison are secondary after the treatment of calf blood protein-removed extraction gel for eye use
Effect occurs.
Preferred forms: drug therapy is used.
Claims (2)
1. a kind of method of drug therapy dry eyes after laser in situ keratomileusis, LASIK postoperative patient, postoperative routine are given
1g L-1 fluorometholone eye drops+3g L-1 ofloxacin eye drops add calf blood protein-removed extraction gel for eye use 4 times a day
And sodium hyaluronate eye drops, add sodium hyaluronate (love is beautiful) eye drops 4 times a day, each treatment 1 month.
2. according to the method described in claim 1, it is characterized in that: plus calf blood protein-removed extraction gel for eye use and sodium hyaluronate
Eye drops adds sodium hyaluronate (love is beautiful) eye drops 4 times a day, each treatment 1 month.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711079199.1A CN109745340A (en) | 2017-11-06 | 2017-11-06 | A kind of method of drug therapy dry eyes after laser in situ keratomileusis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711079199.1A CN109745340A (en) | 2017-11-06 | 2017-11-06 | A kind of method of drug therapy dry eyes after laser in situ keratomileusis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109745340A true CN109745340A (en) | 2019-05-14 |
Family
ID=66400968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711079199.1A Pending CN109745340A (en) | 2017-11-06 | 2017-11-06 | A kind of method of drug therapy dry eyes after laser in situ keratomileusis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109745340A (en) |
-
2017
- 2017-11-06 CN CN201711079199.1A patent/CN109745340A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xia et al. | Comparison of the femtosecond laser and mechanical microkeratome for flap cutting in LASIK | |
| Whitman et al. | Treatment of presbyopia in emmetropes using a shape-changing corneal inlay: one-year clinical outcomes | |
| Ferguson et al. | Clinical evaluation of a trabecular microbypass stent with phacoemulsification in patients with open-angle glaucoma and cataract | |
| Janani et al. | MyoRing implantation in keratoconic patients: 3 years follow-up data | |
| Craig et al. | BCLA CLEAR Presbyopia: Management with corneal techniques | |
| Chen et al. | Effect of brimonidine tartrate 0.2% ophthalmic solution on visual quality after implantable collamer lens implantation with a central hole | |
| Napoli et al. | A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops | |
| US11596641B2 (en) | Methods and compositions for treating meibomian gland dysfunction | |
| Karakaya et al. | 5-Fluorouracyl added infusion fluid in patients with recurrent rhegmatogeneous retinal detachment | |
| Dawodu et al. | Prevalence and causes of blindness in Otibhor Okhae teaching hospital, Irrua, Edo State, Nigeria | |
| CN109745340A (en) | A kind of method of drug therapy dry eyes after laser in situ keratomileusis | |
| Watkinson | Assessment and management of patients with acute red eye | |
| Zukaite et al. | Influence of peripheral corneal relaxing incisions during cataract surgery for corneal astigmatism up to 2.5 dioptres on corneal densitometry | |
| TRATTLER et al. | Clinical Utility of Amniotic Membranes | |
| Hamed et al. | Evaluation of Higher Order Aberrations after Cross-linking in patients with early Keratoconus | |
| Wagner et al. | Iatrogene Keratektasie nach refraktiver Chirurgie–Ursachen, Prophylaxe, Therapie | |
| Ribeiro | A retrospective analysis of dry eye interventions during the first postoperative year of patients undergoing LASIK versus PRK | |
| Martin | Corneal conjunctivalization management with high Dk RGP contact lenses | |
| Ferrini et al. | A pilot study on Langerhans cells in keratoconus patients by in vivo confocal microscopy before and after corneal cross-linking and correlation with eye rubbing | |
| Kuhn-Wilken | An OD's Guide to Postoperative Cataract Care: Practical advice for both routine and complex cases | |
| Chean et al. | Deep sclerectomy-trabeculectomy with mitomycin C in treating glaucoma: postoperative long-term results | |
| Lafosse | Changes in tear film metrics and ocular signs induced by different types of refractive correction in an aging population | |
| Tian | Management and outcomes after Trans-Epithelium Photorefractive Keratectomy and Laser-Assisted Sub-Epithelium Keratectomy in the COVID-19 Epidemic | |
| Rath | Indications and visual outcome following optical keratoplasty and their correlation with graft failure. | |
| Medhat Siam Abd El-Haleem et al. | CORNEAL BIOMECHANICAL CHANGES POST-FLAPLESS FEMTO REFRACTIVE PROCEDURE VS FEMTO-LASIK IN MYOPIC EYES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190514 |